

EIRINI VASARMIDI MD, MSc, PhD
Pulmonologist, Assistant Professor (elected)
School of Medicine, University of Crete
Heraklion, Crete, Greece
e-mail: eirvasar@gmail.com

EDUCATION

Sept 2007 - July 2013	School of Medicine, University of Crete Medical Doctor
Oct 2012 - February 2013	School of Medicine, University of Graz, Austria ERASMUS exchange program
Sept 2013 - July 2015	School of Medicine, University of Crete MSc "Molecular Basis of Human Diseases" Graduated top of the class
June 2016 – Nov 2019	School of Medicine, University of Crete PhD "Mitophagy and oxidation status of mitochondria in IPF Macrophages" Laboratory of Molecular and Cellular Pneumology Supervisor: Prof. Katerina M. Antoniou

PROFESSIONAL EXPERIENCE

October 2015 – December 2020	University Hospital of Heraklion, Crete Residency in Pulmonology- Department of Respiratory Medicine (21/12/2020 successfully passed the specialty examination)
February 2021- May 2021	INSERM, UMR1152, Labex Inflamex, FHU APOLLO Université de Paris, Faculté de médecine Xavier Bichat, Paris Post-doctoral Researcher Supervisor: Prof Bruno Crestani
June 2021-June 2022	INSERM, UMR1152, Labex Inflamex, FHU APOLLO Université de Paris, Faculté de médecine Xavier Bichat, Paris ERS Fellow (Long Term Research Fellowship) Supervisor: Prof Bruno Crestani
June 2022 – May 2023	University Hospital of Heraklion, Crete Pulmonologist
September 2022- Pending	School of Medicine, University of Crete Teaching Assistant
September 2023- Pending	University Hospital of Heraklion, Crete Pulmonologist, Assistant Consultant

AWARDS

2007	Institute of National Awards <i>Top of the Class of 2007</i> , Medical University of Crete
2015	24 th Hellenic Thoracic Society Congress, Athens Greece, Nov 2015 <u>Research Award</u> : "Investigation of Mitochondria homeostasis in Idiopathic Pulmonary Fibrosis (IPF) macrophages- a mitophagy study in bronchoalveolar lavage fluid." (15000 euros)

- 2015 24th Hellenic Thoracic Society Congress, Athens Greece, Nov 2015
Oral presentation in ILDs session: "Investigation of Mitochondria homeostasis in Idiopathic Pulmonary Fibrosis (IPF) macrophages- a mitophagy study in bronchoalveolar lavage fluid."
E. Vasarmidi, E. Tsitoura, S. Michelakis, C. Koutoulaki, G. Margaritopoulos, I. Charalampous, I. Lampiri, N. Tzanakis, D. Georgopoulos, KM Antoniou
- 2015 24th Hellenic Thoracic Society Congress, Athens Greece, Nov 2015
e-poster award: "Expression of DNA methyltransferase 1 and Cyclin D2, as well as of miR-185, in BALF cells from patients with IPF and lung cancer." E. Bibaki, E. Tsitoura, C. Koutoulaki, **E. Vasarmidi**, I. Lampiri, N. Tzanakis, D. Georgopoulos, K. Antoniou.
- 2016 25th Hellenic Thoracic Society Congress, Athens, Greece, June 2016
Oral presentation: "MiR-185/AKT and MiR-29a/Collagen1a pathways are activated in IPF alveolar macrophages."
E. Vasarmidi, E. Tsitoura, AU Wells, C. Koutoulaki, K. Karagiannis, I. Lasithiotaki, H. Sato, AD Spandidos, D. Georgopoulos, G. Sourvinos, KM Antoniou
- 2016 25th Hellenic Thoracic Society Congress, Athens, Greece, June 2016
Best study published in international journal:
"NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung." I. Lasithiotaki, I. Giannarakis, E. Tsitoura, KD Samara, G. Margaritopoulos, C. Choulaki, **E. Vasarmidi**, N. Tzanakis, A. Voloudaki, P. Sidiropoulos, NM Siafakas, KM Antoniou
- 2017 26th Hellenic Thoracic Society Congress, Athens, Greece, Nov 2017
Oral presentation: "Mitochondrial homeostasis in BALF cells of IPF patients."
- 2020 Graduate excellence for PhD students for the academic year 2018-2019, Foundation "Maria M. Manassaki", University of Crete
- 2020 29th Hellenic Thoracic Society Congress, Athens Greece, Dec 2020
Oral presentation in the ILDs session: Early COVID-19 Lockdown in Greece and IPF: A beneficial "impact" beyond any expectation".
S. Papiris, D. Bouros, K. Markopoulou, L. Kolilekas, A. Papaioannou, V. Tzilas, A. Tzouvelekis, E. Fouka, D. Papakosta, Z. Daniil, P. Steiropoulos, A. Gogali, I. Papanikolaou, A. Xyfteri, A. Haritou, I. Korbila, I. Tomos, S. Loukides, R. Bellelli, G. Kounti, C. Rampiadou, T. Karampitsakos, I. Dimeas, P. Kirgou, A. Bompoki, **E. Vasarmidi**, K. Loverdos, E.M. Antonogiannaki, M. Blizou, E. Bouros, K. K. Kagouridis, M. Maniati, A. Karakatsani, K. Antoniou, E. Manali
- 2022 31th Hellenic Thoracic Society Congress, Athens Greece, Dec 2022
Research Award: "The role of the anti-aging protein, a-Klotho, on metabolism and mitochondrial homeostasis of monocytes/macrophages in IPF patients and patients with progressive pulmonary fibrosis." (15000 euros)
- 2022 31th Hellenic Thoracic Society Congress, Athens Greece, Dec 2022
Oral presentation in the ILDs session: "Radiological Features, Immune Background and Outcomes of Patients with Myositis Associated- Interstitial Lung Disease: a Multicenter Study."
T. Karampitsakos, V. Tzilas, O. Papaioannou, S. Chrysikos, **E. Vasarmidi**, PA. Juge, S. Vizirianaki, E. Bibaki, A. Reppa, P. Sidiropoulos, M. Katsaras, V. Sotiropoulou, P. Tsiri, E. Koulousousa, E. Theochari, G. Tsirikos, I. Christopoulos, E. Malakounidou, E. Zarkadi, F. Sampsonas, G., Hillas, T. Karageorgas, D. Daoussis, C. Kalogeropoulou, K. Dimakou, N. Tzanakis, R. Borie, P. Dieudé, K. Antoniou, B. Crestani, D. Bouros, A. Tzouvelekis

MEDICAL AND SCIENTIFIC SOCIETIES

2010-2012	Hellenic Medical Student Association Member of the Organizing Board of the 16 th and 17 th Hellenic Medical Students' Congress
2011-2012	Hellenic Medical Student Association Member of the Directing Board, Local Chapter
2013-pending	Doctors of the Aegean Sea – University Hospital of Heraklion Voluntary Association
2015-pending	Member of the Hellenic Thoracic Society (HTS) and the European Respiratory Society (ERS)
2022-pending	European Respiratory Society (ERS) Task Force Member - <i>ERS Research Statement on long COVID follow-up (published – 2nd author)</i> - <i>An official European Respiratory Society research statement: diagnosis and management of post-COVID interstitial lung disease (ongoing – ERS TF-2022-09)</i>
2023-pending	European Respiratory Society (ERS) Member of College of Experts - <i>Reviewing of applications for the RESPIRE4 Marie Skłodowska-Curie Fellowship Programme 2023</i> - <i>Reviewing of abstracts and clinical cases submitted for the ERS Congress 2024 (Reviewing topic: 03.01 - Molecular pathology and functional genomics)</i> - <i>ERS Awards Reviewer</i>
2024-pending	Early Career Member (ECM) Representative of Interstitial Lung Diseases (ILD) Group of the Hellenic Thoracic Society (HTS)
2023-pending	Member of the EULAR study group for lung manifestations in Rheumatic and Musculoskeletal Diseases (RMD) – Young Investigators
2024-pending	Member of the European Respiratory Society (ERS) Methodology Network

RESEARCH EXPERIENCE

April 2014-August 2014	University of Crete, School of Medicine Laboratory of Clinical Virology “Viral Susceptibility of Human Nucleus Pulposus Cells” Supervisor: Prof. George Sourvinos
August 2014-June 2015	University of Crete, School of Medicine Laboratory of Molecular and Cellular Pneumology Master Thesis: “Mitochondrial status in IPF – a study in bronchoalveolar lavage fluid cells.” Supervisor: Ass Prof. Katerina M. Antoniou
June 2016- November 2019	University of Crete, School of Medicine Laboratory of Molecular and Cellular Pneumology PhD thesis: “Mitophagy and oxidation status of mitochondria in IPF macrophages”. Supervisor: Ass Prof. Katerina M. Antoniou
February 2021 – June 2021	INSERM, UMR1152, Labex Inflamex, FHU APOLLO Université de Paris, Faculté de médecine Xavier Bichat Post-doctoral position: “Epithelial cell fate in Idiopathic Pulmonary

Fibrosis.”
Supervisor: Prof Bruno Crestani

June 2021- June 2022
INSERM, UMR1152, Labex Inflammex, FHU APOLLO
Université de Paris, Faculté de médecine Xavier Bichat
ERS Long Term Research Fellowship: “Partial Apoptosis of epithelial cells in Idiopathic Pulmonary Fibrosis.”
Supervisor: Prof Bruno Crestani

TEACHING EXPERIENCE

2019
Lecture in the Post Graduate Course 5 in ERS Congress (PG5 - Novel insights into the diagnostic algorithm for interstitial lung diseases).
“Lung ultrasound in the assessment of Idiopathic Pulmonary Fibrosis”
(invited lecture on payment).

2022-2023 & 2023-2024
Lectures in Pathophysiology
“Pathophysiology of Pleural Lung Disease and Fibrotic Lung Diseases”
Medical School, University of Crete, 5th semester

2022-2023 & 2023-2024
Clinical training and lectures for undergraduate students (6th semester)
Respiratory Department, University Hospital of Heraklion

2022-2023 & 2023-2024
Lectures in Internal Medicine-Pulmonology
“Vasculitis and the lung” and
“Novel diagnostic techniques for lung diseases”
Medical School, University of Crete, 7th semester

2021- Pending
Postgraduate Lectures in the residents' educational program of the
Respiratory Department, University Hospital of Heraklion

ORAL PRESENTATIONS

2015
ERS International Congress, Amsterdam Netherlands, September 2015
“Investigation of Mitochondria homeostasis and mitophagy in
Bronchoalveolar lavage fluid (BALF) cells in pulmonary fibrosis.”

2016
25th Hellenic Thoracic Society Congress, Athens, Greece, June 2016
“MiR-185/AKT and MiR-29a/Collagen1a pathways are activated in IPF
alveolar macrophages.”

2017
7th International Meeting on Pulmonary Rare Diseases and Orphan
Drugs, Milan, Italy, February 2017
“Mitochondrial homeostasis in IPF alveolar macrophages: Increased
levels of mitochondrial ROS and possible link with mitophagy and
autophagy.”

2017
Cretan Summer School of Respiratory Department (SHARE), Interstitial
Lung Diseases Course: From Bench to Bedside, Heraklion, Greece, July
2017, “Mitochondrial Homeostasis in IPF BALF cells.”

2017
26th Hellenic Thoracic Society Congress, Athens, Greece, Nov 2017
“Mitochondrial homeostasis in BALF cells of IPF patients.”

2018
WASOG 2018, Heraklion, Crete, Greece, June 2018
“Alveolar macrophages show elevated oxidized mitochondria levels in
IPF. Possible link with mitophagy and autophagy.”

2019
ERS International Congress, Madrid, Spain, September 2019
Postgraduate Course (PG5) -Novel insights into the diagnostic algorithm
for interstitial lung diseases; “Lung ultrasound in the assessment of
Idiopathic Pulmonary Fibrosis.”

2019	7 th Hellenic Seminar of Interstitial Lung Diseases, Thessaloniki, Greece, November 2019 – Case presentation
2022	2 nd Cretan Summer School of Respiratory Department (SHARE 2), Heraklion, Crete, Greece, June-July 2022 “Lung Echo in ILDs: Clinical Applications.”
2022	2 nd Cretan Summer School of Respiratory Department (SHARE 2), Heraklion, Crete, Greece, June-July 2022 “Vasculitis and the Lung”
2022	What is New in Respiratory Medicine 2022, Ioannina, Greece, Sept 2022 “Updated Guidelines for IPF”
2023	10 th International Meeting on Pulmonary Rare Diseases and Orphan Drugs, Milan, Italy, March 2023 “Characteristics of BALF cells in patients with post COVID-19 pulmonary sequelae”
2023	3 rd Cretan Summer School of Respiratory Department (SHARE 3), Heraklion, Crete, Greece, June-July 2023 “Rheumatic Diseases and Lung Echo”
2023	15 th National Conference of Musculoskeletal health (EPEMY), Heraklion, Crete, Greece, September 2023 “Scleroderma and Pulmonary Fibrosis”
2023	32 th Hellenic Thoracic Society Congress, Athens, Greece, December 2023 Practical Workshop of Interstitial Lung Diseases- Clinical cases
2023	32 th Hellenic Thoracic Society Congress, Athens, Greece, December 2023 “Predictive factors of mortality in fibrotic Interstitial Lung Diseases; a retrospective single-center study.”
2024	1st Educational Seminar: Fibrosis Across Organ Systems National Hellenic Research Foundation, Athens, Greece, January 2024 “The role of anti-fibrotic compounds in the management of fibrosis; The role of pirfenidone.”
2024	e-Masterclass on Systemic Sclerosis Interstitial Lung Disease (SSc ILD). “Current practice of management of SSC-ILD, Cases of SSc-ILD plus PAH.” April 2024
2024	4 th Cretan Summer School of Respiratory Department (SHARE 4), Heraklion, Crete, Greece, June 2024 “Leukocyte telomere length: the dawn of a new era of personalized medicine in fibrotic interstitial lung diseases?”
2024	Global Southeast Asian Webinars, Session 1, July 2024 “Research Update: Post COVID-19”

CHAIRING IN CONGRESSES

2022	2 nd Cretan Summer School of Respiratory Department (SHARE 2), Heraklion, Crete, Greece, June-July 2022 PRO-CON debate: Cryobiopsy vs Genomic Classifier in IPF
2022	31 th Hellenic Thoracic Society Congress, Athens, Greece, December 2022 Oral Presentation Session - Interstitial Lung Diseases
2023	2 nd Bridges of Pulmonology, Patras, Greece, June 2023

2023	3 rd Cretan Summer School of Respiratory Department (SHARE 3), Heraklion, Crete, Greece, June-July 2023 Lecture: Just breathe: a review of sex and gender in chronic lung disease
2023	9 th National Conference of Public Health & Social Medicine Forum, Heraklion, Crete, Greece, October 2023 Research Session: Two-slide presentation of interesting research topics
2023	32 th Hellenic Thoracic Society Congress, Athens, Greece, December 2023 Oral Presentation Session - Interstitial Lung Diseases
2024	PanEuropean Webinar: Respiratory Medicine meets other Disciplines Member of the Organizing Committee and Discussant, May 2024
2024	3 rd Bridges of Pulmonology, Patras, Greece, June 2024 Commentator in the session: "Practical Approaches and Challenges in. Interstitial Lung Diseases" and Member of the Scientific Committee

CLINICAL TRIALS

Subinvestigator Respiratory Department, University Hospital of Heraklion, Crete, Greece

- "A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)." / FIBRONEER Trial IPF/ NCT05321069 / Boehringer Ingelheim
- "A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)." / FIBRONEER Trial PF-ILDs / NCT05321082/ Boehringer Ingelheim
- "A phase III open-label extension study to evaluate long-term safety and efficacy of PRM-151 in patients with Idiopathic Pulmonary fibrosis (IPF)." / STARSCAPE WA42293 / NCT04552899 / F. Hoffmann-La Roche Ltd
- "An interventional study without an investigational medicinal product to differentially diagnose patients with interstitial lung diseases (ILDs), to monitor disease progression, and to identify molecular markers." (0352-2144-FSP) / Boehringer Ingelheim
- "A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF)." / ELEVATE (LYT-100 in IPF) / NCT05321420 / PureTech
- "A randomized, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally." / NCT04419506 / Boehringer Ingelheim
- "A phase III randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with Idiopathic Pulmonary Fibrosis (IPF)." / STARSCAPE WA42293 / NCT04552899 / F. Hoffmann-La Roche Ltd

PUBLICATIONS IN INTERNATIONAL PEER REVIEWED JOURNALS

1. G. Margaritopoulos, **E. Vasarmidi**, AU. Wells, KM. Antoniou. Smoking and Interstitial Lung Diseases: What's New. European Respiratory Review. Sept 2015.
2. Lasithiotaki I, Giannarakis I, Tsitoura E, Samara KD, Margaritopoulos GA, Choulaki C, **Vasarmidi E**, Tzanakis N, Voloudaki A, Sidiropoulos P, Siafakas NM, Antoniou KM. NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung. Eur Respir J. 2016 Mar;47(3):910-8.
3. G. Margaritopoulos, **E. Vasarmidi**, KM Antoniou. Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid. 2016 Jul 1;11:11-22.

4. E. Tsitoura, AU Wells, K. Karagiannis, I. Lasithiotaki, **E. Vasarmidi**, E. Bibaki, C. Koutoulaki, H. Sato, DA Spandidos, NM Siafakas, G. Sourvinos, KM Antoniou. MiR-185/AKT and miR-29a/Collagen 1a pathways are activated in IPF BAL cells. *Oncotarget*. 2016 Nov 15;7(46):74569-74581.
5. Bibaki E, Tsitoura E, **Vasarmidi E**, Margaritopoulos G, Trachalaki A, Koutoulaki C, Georgopoulou T, Spandidos DA, Tzanakis N, Antoniou KM. miR-185 and miR-29a are similarly expressed in the bronchoalveolar lavage cells in IPF and lung cancer but common targets DNMT1 and COL1A1 show disease specific patterns. *Mol Med Rep*. 2018 May;17(5):7105-7112.
6. **Vasarmidi E***, Sarantoulaki S*, Trachalaki A, Margaritopoulos G, Bibaki E, Spandidos DA, Tzanakis N, Antoniou K. Investigation of key autophagy-and mitophagy-related proteins and gene expression in BALF cells from patients with IPF and RA-ILD. *Mol Med Rep*. 2018 Oct;18(4):3891-3897.
7. Proklou A, Bolaki M, Vassalou EE, Bibaki E, **Vasarmidi E**, Margaritopoulos GA, Karantanis AH, Tzanakis N, Antoniou KM. Paroxysmal cough and left sacroiliac joint pain in a 50-year-old Caucasian man. *Breathe (Sheff)*. 2018 Jun;14(2):e59-e67.
8. Alpantaki K, Zafiropoulos A, Tseliou M, **Vasarmidi E**, Sourvinos G. Herpes simplex virus type-1 infection affects the expression of extracellular matrix components in human nucleus pulposus cells. *Virus Res*. 2019 Jan 2;259:10-17.
9. Margaritopoulos GA, Trachalaki A, Wells AU, **Vasarmidi E**, Bibaki E, Papastratigakis G, Detorakis S, Tzanakis N, Antoniou KM. Pirfenidone improves survival in IPF: results from a real-life study. *BMC Pulm Med*. 2018 Nov 23;18(1):177.
10. Daniil Z, Kotsiou OS, Grammatikopoulos A, Peletidou S, Gkika H, Malli F, Antoniou K, **Vasarmidi E**, Mamuris Z, Gourgoulisanis K, Zifa E. Detection of mitochondrial transfer RNA (mt-tRNA) gene mutations in patients with idiopathic pulmonary fibrosis and sarcoidosis. *Mitochondrion*. 2018 Nov;43:43-52.
11. Antoniou KM, Tzilas V, **Vasarmidi E**, Symvoulakis EK, Tzouvelekis A, Bouros D. Interstitial lung abnormalities: ignotum per ignotius. *Lancet Respir Med*. 2019 May;7(5):376-378.
12. Tsitoura E.*, **Vasarmidi E.***, Bibaki E., Trachalaki A., Koutoulaki C. Papastratigakis G., Papadogiannaki S., Chalepakis G., Tzanakis N., Antoniou KM. Accumulation of damaged mitochondria in alveolar macrophages with reduced OXPHOS related gene expression in IPF. *Respir Res*. 2019 Nov 27;20(1):264.
13. Antoniou KM, Trachalaki A, Tzouvelekis A, Poletti V, **Vasarmidi E**, Sfrikakis P, Bouros D. A role of antifibrotics in the treatment of Scleroderma-ILD? *Pulmonology*. 2019 Oct 22. pii: S2531-0437(19)30168-0.
14. Antoniou KM*, Markopoulou K*, Tzouvelekis A*, Trachalaki A*, **Vasarmidi E***, Organtzis J, Tzilas V, Bouros E, Kounti G, Rampiadou C, Kotoulas SC, Bardaka F, Bibaki E, Fouka E, Meletis G, Tryfon S, Daniil Z, Papakosta D, Bouros D. Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. *ERJ Open Res*. 2020 Jan 27;6(1):00172-2019.
15. Tsitoura E, Bibaki E, Bolaki M, **Vasarmidi E**, Trachalaki A, Symvoulakis EK, Spandidos DA, Antoniou KM. [Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. *Exp Ther Med*. 2020 Jul;20(1):147-150.
16. **Vasarmidi E**, Tsitoura E, Spandidos DA, Tzanakis N, Antoniou KM. Pulmonary fibrosis in the aftermath of the COVID-19 era (Review). *Exp Ther Med*. 2020 Sep;20(3):2557-2560.
17. Papiris SA, Bouros D, Markopoulou K, Kolilekas L, Papaioannou AI, Tzilas V, Tzouvelekis A, Fouka E, Papakosta D, Daniil Z, Steiropoulos P, Gogali A, Papanikolaou IC, Xyfteri A, Haritou A, Korbila I, Tomos IP, Loukides S, Bellelli R, Kounti G, Rampiadou C, Karampitsakos T, Dimeas I, Kirgou P, Bompoki A, **Vasarmidi E**, Loverdos K, Antonogiannaki EM, Blizou M, Bouros E,

Kagouridis K, Maniati M, Karakatsani A, Antoniou KM, Manali ED. Early COVID-19 Lockdown in Greece and IPF: A beneficial "impact" beyond any expectation. *Eur Respir J*. 2020 Dec 17:2003111.

18. Antoniou KM, Tsitoura E, **Vasarmidi E**, Symvoulakis EK, Aidinis V, Tzilas V, Tzouvelekis A, Bouros D. Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care. *Curr Opin Pharmacol*. 2021 Feb 5;57:71-80.
19. Karampitsakos T, Torrisi S, Antoniou K, Manali E, Korbila I, Papaioannou O, Sampsonas F, Katsaras M, **Vasarmidi E**, Papakosta D, Domvri K, Fouka E, Organtzis I, Daniil Z, Dimeas I, Kirgou P, Gourgoulialis KI, Papanikolaou IC, Markopoulou K, Kounti G, Tsapakidou E, Papadopoulos E, Tatsis K, Gogali A, Kostikas K, Tzilas V, Chrysikos S, Papiris S, Bouros D, Kreuter M, Tzouvelekis A. Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis. *Respir Res*. 2021 May 5;22(1):140.
20. Trachalaki A, Tsitoura E, Mastrodimou S, Invernizzi R, **Vasarmidi E**, Bibaki E, Tzanakis N, Molyneaux PL, Maher TM, Antoniou K. Enhanced IL-1 β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis. *Front Immunol*. 2021 Jun 15;12:661811.
21. Pitsidianakis G, Vassalou EE, **Vasarmidi E**, Bolaki M, Klontzas ME, Xirouchaki N, Georgopoulos D, Karantanis AH, Tzanakis N, Antoniou KM. Performance of Lung Ultrasound for Monitoring Interstitial Lung Disease. *J Ultrasound Med*. 2021 Jul 22.
22. Bizymi N, Pitsidianakis G, Ierodiakonou D, Stathakis G, **Vasarmidi E**, Hiraki S, Bolaki M, Karagiannis K, Fanaridis M, Liopyrakis K, Marinos L, Xilouri I, Antoniou KM, Tzanakis N. Case Report: Diagnosis of Myelodysplastic Syndrome in a 72-Year-Old Female With Interstitial Lung Disease. *Front Med (Lausanne)*. 2021 Aug 9;8:673573.
23. Tsitoura E, Trachalaki A, **Vasarmidi E**, Mastrodimou S, Margaritopoulos GA, Kokosi M, Fanidis D, Galaris A, Aidinis V, Renzoni E, Tzanakis N, Wells AU, Antoniou KM. Collagen 1a1 expression by airway macrophages increases in fibrotic ILDs and is associated with FVC decline and increased mortality. *Frontiers in Immunology*. *Front Immunol*. 2021 Nov 17;12:645548.
24. Antoniou KM, **Vasarmidi E***, Russell AM*, Andrejak C, Crestani B, Delcroix M, Dinh-Xuan AT, Poletti V, Sverzellati N, Vitacca M, Witzenzrath M, Tonia T, Spanevello A. European Respiratory Society Statement on Long COVID-19 Follow-Up. *Eur Respir J*. 2022 Feb 10:2102174.
25. M'Kacher R, Jalliet M, Colicchio B, **Vasarmidi E**, Mailleux A, Dieterlen A, Kannengiesser C, Borie C, Oudrhiri N, Junker S, Voisin P, Jeandidier E, Carde P, Fenech M, Bennaceur-Griscelli A, Crestani B, Borie R. Lung Fibroblasts from Idiopathic Pulmonary Fibrosis Patients Harbor Short and Unstable Telomeres Leading to Chromosomal Instability. *Biomedicines*. 2022 Jan 28;10(2):310.
26. Justet A, Ghanem M, Boghanim T, Hachem M, **Vasarmidi E**, Jalliet M, Vadel A, Joannes A, Mordant P, Bonniaud P, Kolb M, Ling L, Cazes A, Mal H, Mailleux A, Crestani B. FGF19 is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice. *Am J Respir Cell Mol Biol*. 2022 May 12.
27. **Vasarmidi E**, Hindre R, Uzunhan Y, Borie R, Crestani B. Whatever 'smells' like COVID-19 is not always COVID-19. *Rheumatol Adv Pract*. 2022 Jul 26;6(2):rkac063.
28. **Vasarmidi E**, Ghanem M, Crestani B. Interstitial lung disease following coronavirus disease 2019. *Curr Opin Pulm Med*. 2022 Sep 1;28(5):399-406.
29. Karampitsakos T, Tzilas V, Papaioannou O, Chrysikos S, **Vasarmidi E**, Juge PA, Vizirianaki S, Bibaki E, Reppa A, Sidiropoulos P, Katsaras M, Sotiropoulou V, Tsiri P, Koulousousa E, Theochari E, Tsirikos G, Christopoulos I, Malakounidou E, Zarkadi E, Sampsonas F, Hillas G, Karageorgas T, Daoussis D, Kalogeropoulou C, Dimakou K, Tzanakis N, Borie R, Dieudé P, Antoniou K, Crestani B, Bouros D, Tzouvelekis A. Clinical features and outcomes of patients with myositis associated-interstitial lung disease. *Front Med (Lausanne)*. 2023 Jan 9;9:1096203.
30. Visca D*, Centis R*, Pontali E*, Zampogna E*, Russell AM*, Migliori GB*, Andrejak C, Aro M, Bayram H, Berkani K, Bruchfeld J, Chakaya JM, Chorostowska-Wynimko J, Crestani B, Dalcolmo MP, D'Ambrosio L, Dinh-Xuan AT, Duong-Quy S, Fernandes C, García-García JM, Kawassaki

AM, Carrozzi L, Martinez-Garcia MA, Martins PC, Mirsaeidi M, Mohammad Y, Naidoo RN, Neuparth N, Sese L, Silva DR, Solovic I, Sooronbaev TM, Spanevello A, Sverzellati N, Tanno L, Tiberi S, Vasankari T, **Vasarmidi E**, Vitacca M, Annesi-Maesano I*. Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease. 2023. *Int J Tuberc Lung Dis*. 2023 Oct 1;27(10):729-741.

31. Symvoulakis EK, **Vasarmidi E**, Linardakis M, Tsiavos A, Mantadaki AE, Pitsidianakis G, Karelis A, Petraki C, Nioti K, Mastronikolis S, Tzanakis N, Antoniou KM. Assessing feasibility of targeted primary care referrals for patients with clinical suspicion of interstitial lung disease using lung ultrasound: a prospective case finding study. *Sarcoidosis, Vasculitis and Diffuse Lung Diseases*. 2023. Jun 29;40(2):e2023022.
32. Ioannou P, Akoumianakis I, Filippatos TD, Akoumianaki E, Chamilos G, Kofteridis DP, On Behalf of The University Hospital of Heraklion COVID-19 Study Group. High-Flow Nasal Oxygen For Severe COVID-19 Pneumonia In Greek Patients: A Prospective Observational Study. *Kurume Med J*. 2023 Nov 30;69(1.2):53-63. (Full authors' list in Appendix)
33. Calaraş D., David A., **Vasarmidi E**, Antoniou K. and Corlăteanu A. Hypersensitivity pneumonitis: challenges of a complex disease. *Can Respir J*. 2024 Jan 18;2024:4919951.
34. A.M. Matthaïou, N. Bizymi, K. Pagonidis, E. Manousaki, M. Fragkoulakis, I. Lambiri, I. Mitrouska, **E. Vasarmidi**, N. Tzanakis and K.M. Antoniou. Reversibility of the enlargement of the pulmonary artery in COVID-19 pneumonia as a marker of remission of the disease. *J Pers Med*. 2024 Jan 31;14(2):161.
35. PA. Juge, J.A. Sparks, S. Gazal, R. Borie, MP. Debray, C. Kannengiesser, G. McDermott, T. Doyle, C. van Moorsel, B.M. Boxma-de Klerk, **E. Vasarmidi**, K. Antoniou, A.H. M. van der Helm, C. Boileau, B. Crestani and P. Dieudé. RPA3-UMAD1 rs12702634 and Rheumatoid Arthritis-Associated Interstitial Lung Disease in European Ancestry. *RHEUMAP-2023-172. Rheumatol Adv Pract*. 2024 Jun 4;8(2):rkae059.
36. **E. Vasarmidi**#, I. Lambiri, E. Foteinaki, V. Stamatopoulou, I. Mitrouska, G. Pitsidianakis, A. Patrianakis, A. Plevritaki, S. Michelakis, V. Amargianitakis, G. Prinianakis, S. Schiza, N. Tzanakis. Two women with unexplained dyspnea; Removing the blame game from the lungs. *Breathe (Sheff)*. 2024 Aug 27;20(2):240029.
37. M. Ghanem, A. Justet, **E. Vasarmidi**, T. Boghanim, M. Hachem, A. Vadel, A. Joannes, P. Mordant, A. Balayev, T. Adams, M. Jaillet, H. Mal, A. Cazes, N. Pote, A. Mailleux and B. Crestani. Identification of FGFR4 as a regulator of myofibroblast differentiation in Pulmonary Fibrosis. L-00184-2023. *Am J Physiol Lung Cell Mol Physiol*. 2024 Oct 1.
38. I. Bouloukaki*, S. Michelakis*, E. Tsitoura, **E. Vasarmidi**, C. Koutoulaki, N. Tzanakis, S. Schiza† and KM. Antoniou†. KL-6, ET-1 and S100A9 levels in patients with Idiopathic Pulmonary Fibrosis (IPF) and Obstructive sleep apnoea (OSA). *Exp Ther Med* (accepted)
39. **E. Vasarmidi**, N. Bizymi, K. Lyroni, AM. Matthaïou, I. Lambiri, E. Bibaki, D. Kofteridis, S. Schiza, N. Tzanakis and KM. Antoniou. Bronchoscopy as a sensitive tool for prolonged COVID-19 diagnosis in B cell-depleted patients after Rituximab treatment: a case series. *Biomedical Reports* (under revision)

*Those authors contributed equally
#Corresponding author

CHAPTERS

1. Antoniou K.M., **Vasarmidi E**., Trachalaki A., Bibaki E., Crestani B. Systemic lupus erythematosus, Sjögren's syndrome and mixed connective tissue disease. ERS Monograph. Chapter 7. December 2019. In book: *Pulmonary Manifestations of Systemic Diseases*. DOI: 10.1183/2312508X.10014319
2. **Vasarmidi E**. Acute Interstitial Pneumonia (AIP). In book: *Clinical Pneumonology – 3rd Edition*. By: D. Polyzogopoulos and V. Polychronopoulos. Publisher: Paschalidis. January 2022

3. Ghanem M.*, **Vasarmidi E.***, Morer L, Le Guen P, Crestani B. (2023). Lung Disease in Systemic Lupus Erythematosus, Myositis, Sjögren's Disease, and Mixed Connective Tissue Disease. In: Cottin, V., Richeldi, L., Brown, K., McCormack, F.X. (eds) Orphan Lung Diseases. Springer, Cham. https://doi.org/10.1007/978-3-031-12950-6_14.
4. **Vasarmidi E.**, Bibaki E., Antoniou KM. Systemic inflammatory diseases with rare lung involvement (incl. Behçet's disease and Takayasu's arteriitis). ERS Monograph. Chapter 6A. June 2023. DOI: 10.1183/2312508X.10018722 In book: Rare Diseases of the Respiratory System
5. **Vasarmidi E.**, Le Guen P, Goletto T., Crestani B. COVID-19 in patients with Interstitial Lung Disease. ERS Monograph. Chapter 14. 2024 In book: COVID-19: An Update. DOI: 10.1183/2312508X.10021023
6. **Vasarmidi E.**, Trachalaki A., Antoniou KM. Organizing Pneumonia. CHAPTER 29. In book: Fibrotic Interstitial Lung Diseases. Taylor & Francis Books. *Invited Chapter (accepted)*

*Those authors contributed equally

PUBLICATIONS IN PEER REVIEWED JOURNALS NON-INDEXED IN PUBMED

1. Tsitoura E., Lasithiotaki I., **Vasarmidi E.**, Sourvinos G., Antoniou KM. Lung Cancer and Idiopathic Pulmonary Fibrosis: From Epigenetics to drug therapy. Pneumon. 2015;28(1):23-25.
2. Tsitoura E., Bibaki E., **Vasarmidi E.**, Antoniou KM. Hot topics in IPF Pathogenesis: ERS and ATS highlights. Pneumon. 2016;29(2):122-124.
3. Bibaki E., Trachalaki A., **Vasarmidi E.**, Antoniou KM. IPAF: Interstitial pneumonia with autoimmune features. A new entity? Pneumon. 2017;30(1):14-16.
4. Lygerou D., Bolaki M., Stylianou K., Margaritopoulos G., Dermitzaki EK, **Vasarmidi E.**, Drosotaki E., Maragkou SA, Paraskevopoulos A., Perisinaki G., Gakiopoulou H., Lambiri I., Tzanakis N., Antoniou KM. Renal Involvement of Sarcoidosis: Case Series and Review of the Literature. Archives of Clinical and Medical Case Reports 3 (2019): 550-559.
5. Antoniou KM., Bolaki M., Bibaki E., **Vasarmidi E.**, Trachalaki A., Tsitoura E., Bouros D. COVID19 alert: Do we know our enemy? Pneumon. 2020; 33(1), 25-27.
6. Lyroni K, **Vasarmidi E#**, Tzanakis N, Antoniou KM. Lung infiltrates and fever; is it pneumonia or not? Pneumon 2023;36(2):8.
7. **E. Vasarmidi#***, N. Bizymi*, A.M. Matthaiou, M. Tsagkatakis, E. Bibaki, D. Tamiolakis, C. Skiadas, N. Tzanakis, K.M. Antoniou. Dyspnea and crazy paving on computed tomography; Is it easy to make the diagnosis? Pneumon 2024;37(2):17.
8. N. Galanakis, GA. Kakkos, V. Stamatopoulou, C. Pappas, I. Konstantinou, E. Kehagias, N. Tzanakis, **E. Vasarmidi#**. Treatment challenge in a patient with massive hemoptysis; the need for superselective embolization. Pneumon 2024;37(2):23.

*Those authors contributed equally
Corresponding author

Citations: 1313 (Google Scholar)

h-index: 16 (Google Scholar)

i10-index: 22 (Google Scholar)

ABSTRACTS IN INTERNATIONAL CONGRESSES

- 50 abstracts
 - 13 as 1st author
 - 5 as 2nd author
 - 17 as 3rd author

ABSTRACTS IN NATIONAL CONGRESSES

- 28 abstracts
 - 7 as 1st author
 - 5 as 2nd author
 - 4 as 3rd author

REVIEWER IN INTERNATIONAL JOURNALS

1. European Respiratory Journal (ERJ)
2. European Respiratory Journal Open Research (ERJ Open Res)
3. European Respiratory Review (ERR)
4. Respiratory Research
5. Frontiers
6. Biomedicines
7. International Journal of Molecular Sciences
8. Breath
9. BMJ
10. Heliyon

EDITOR IN INTERNATIONAL JOURNALS

- Topic Editor in *Frontiers in Medicine*: "Pulmonary Involvement in Connective Tissue Diseases: from Diagnostic Tools to Therapeutic Strategies"
- Member of the Editorial Board of *Respiratory Research* Journal
- Guest Editor in the *International Journal of Molecular Sciences*, Special Issue "Molecular Diagnostics and Treatment Advances in Lung Diseases"

PERSONAL DATA

DATE OF BIRTH	28/09/1989
PLACE OF BIRTH	Ierapetra, Crete, Greece
LANGUAGES	Greek (Native), English (Full Professional Proficiency – "Proficiency of Michigan"), German (Limited Working Proficiency – "Zertifikat of Goethe Institute" and "National Certification Level B2"), French (Limited Working Proficiency – "National Certification Level B2")